Kelsay is the President and CEO of the Business Group on Health. She predicts that in 2024, employers will "sound the drug price alarm."
We asked our readers and some members of our editorial advisory board to make predictions for 2024. Here's what Ellen Kelsay had to say:
“Healthcare costs will continue to soar, bringing heightened vigilance by employers as well as concerns about the affordability of medications and medical services. Employers will express growing alarm over the sustainability of and lack of transparency into drug pricing. One hundred percent of employers surveyed have some level of concern related to prescription drug trend, which is greatly fueling overall healthcare trend, according to our 2024 Large Employer Health Care Strategy Survey. Employers will place heightened expectations on their partners to deliver, in large part because of considerations regarding cost, quality and outcomes.”
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
CVS Caremark Makes Changes in Diabetes Coverage for 2025
Published: November 25th 2024 | Updated: November 25th 2024CVS Caremark has removed several diabetes drugs favor of newer products and generics, and is even favoring an insulin infusion system developed by a company that was cofounded by Alan Lotvin, a former executive at CVS Health.
Read More